{"recordsFiltered":49217,"recordsTotal":49217,"next":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=sponsor__name&start=48900","previous":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=sponsor__name&start=48300","results":[{"registry_id":"NCT07227870","publication_url":"https://clinicaltrials.gov/study/NCT07227870","title":"A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma Patients Progressing or Intolerant to Systemic Treatment.","has_exemption":false,"start_date":"2026-02-28","completion_date":"2031-02-28","has_results":false,"results_due":false,"sponsor_name":"Philogen S.p.A.","sponsor_slug":"philogen-spa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07228442","publication_url":"https://clinicaltrials.gov/study/NCT07228442","title":"A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Cutaneous Squamous Cell Carcinoma Patients Progressing on or Intolerant to Systemic Treatment","has_exemption":false,"start_date":"2026-02-28","completion_date":"2031-02-28","has_results":false,"results_due":false,"sponsor_name":"Philogen S.p.A.","sponsor_slug":"philogen-spa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07441174","publication_url":"https://clinicaltrials.gov/study/NCT07441174","title":"A Multicenter, Open-Label, Phase Ib/II Clinical Trial of IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","has_exemption":false,"start_date":"2026-02-28","completion_date":"2031-02-28","has_results":false,"results_due":false,"sponsor_name":"InxMed (Shanghai) Co., Ltd.","sponsor_slug":"inxmed-shanghai-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07365995","publication_url":"https://clinicaltrials.gov/study/NCT07365995","title":"A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer","has_exemption":false,"start_date":"2026-04-22","completion_date":"2031-02-28","has_results":false,"results_due":false,"sponsor_name":"Biontech SE","sponsor_slug":"biontech-se","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07172256","publication_url":"https://clinicaltrials.gov/study/NCT07172256","title":"A Pilot Study of CUE-101 in Combination With Pembrolizumab in Subjects With Newly Diagnosed, Locally Advanced HPV-16 Associated Head and Neck Cancer","has_exemption":false,"start_date":"2026-05-07","completion_date":"2031-02-28","has_results":false,"results_due":false,"sponsor_name":"Yale University","sponsor_slug":"yale-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07227350","publication_url":"https://clinicaltrials.gov/study/NCT07227350","title":"A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-02-28","has_results":false,"results_due":false,"sponsor_name":"Philogen S.p.A.","sponsor_slug":"philogen-spa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07271355","publication_url":"https://clinicaltrials.gov/study/NCT07271355","title":"Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial","has_exemption":false,"start_date":"2026-07-01","completion_date":"2031-02-28","has_results":false,"results_due":false,"sponsor_name":"City of Hope Medical Center","sponsor_slug":"city-of-hope-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07620548","publication_url":"https://clinicaltrials.gov/study/NCT07620548","title":"A Randomized Phase II Study of the Efficacy of Laser Interstitial Thermal Therapy (LiTT) Combined With Cemiplimab Versus Physician's Choice Chemotherapy in Recurrent Glioblastomas","has_exemption":false,"start_date":"2026-08-31","completion_date":"2031-02-28","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05626114","publication_url":"https://clinicaltrials.gov/study/NCT05626114","title":"A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration","has_exemption":false,"start_date":"2023-03-23","completion_date":"2031-03-01","has_results":false,"results_due":false,"sponsor_name":"Genentech, Inc.","sponsor_slug":"genentech-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06912763","publication_url":"https://clinicaltrials.gov/study/NCT06912763","title":"Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)","has_exemption":false,"start_date":"2025-08-08","completion_date":"2031-03-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07511023","publication_url":"https://clinicaltrials.gov/study/NCT07511023","title":"Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum","has_exemption":false,"start_date":"2026-09-25","completion_date":"2031-03-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07564401","publication_url":"https://clinicaltrials.gov/study/NCT07564401","title":"A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-03-03","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07518927","publication_url":"https://clinicaltrials.gov/study/NCT07518927","title":"Mapping Low-Intensity Focused Ultrasound (LIFU)-Evoked Brain Network Responses Using Intracranial Electrophysiological Recordings","has_exemption":false,"start_date":"2026-03-04","completion_date":"2031-03-04","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06042140","publication_url":"https://clinicaltrials.gov/study/NCT06042140","title":"Cryopreserved Human Umbilical Cord as a Meningeal Patch in Fetoscopic Spina Bifida Repair: Single Arm Phase III Trial.","has_exemption":false,"start_date":"2023-09-08","completion_date":"2031-03-08","has_results":false,"results_due":false,"sponsor_name":"The University of Texas Health Science Center, Houston","sponsor_slug":"the-university-of-texas-health-science-center-houston","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06592924","publication_url":"https://clinicaltrials.gov/study/NCT06592924","title":"A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response","has_exemption":false,"start_date":"2025-05-28","completion_date":"2031-03-14","has_results":false,"results_due":false,"sponsor_name":"Canadian Cancer Trials Group","sponsor_slug":"canadian-cancer-trials-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06910813","publication_url":"https://clinicaltrials.gov/study/NCT06910813","title":"An Open-label, Multi-center, Phase I/II Study to Assess Safety, Tolerability and Efficacy of DFT383 in Pediatric Participants With Nephropathic Cystinosis, Followed by a Long-term Extension Phase","has_exemption":false,"start_date":"2025-06-02","completion_date":"2031-03-14","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05538091","publication_url":"https://clinicaltrials.gov/study/NCT05538091","title":"Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","has_exemption":false,"start_date":"2023-05-15","completion_date":"2031-03-17","has_results":false,"results_due":false,"sponsor_name":"Ronald Buckanovich","sponsor_slug":"ronald-buckanovich","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06616597","publication_url":"https://clinicaltrials.gov/study/NCT06616597","title":"Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer","has_exemption":false,"start_date":"2025-02-13","completion_date":"2031-03-30","has_results":false,"results_due":false,"sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsor_slug":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04746677","publication_url":"https://clinicaltrials.gov/study/NCT04746677","title":"Single-Center Investigational Device Exemption Trial: Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)","has_exemption":false,"start_date":"2021-03-15","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Beth Israel Deaconess Medical Center","sponsor_slug":"beth-israel-deaconess-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05064540","publication_url":"https://clinicaltrials.gov/study/NCT05064540","title":"JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization","has_exemption":false,"start_date":"2021-09-20","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Endologix","sponsor_slug":"endologix","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05235165","publication_url":"https://clinicaltrials.gov/study/NCT05235165","title":"A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma","has_exemption":false,"start_date":"2022-04-01","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05605899","publication_url":"https://clinicaltrials.gov/study/NCT05605899","title":"An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)","has_exemption":false,"start_date":"2023-02-10","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Kite, A Gilead Company","sponsor_slug":"kite-a-gilead-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06007677","publication_url":"https://clinicaltrials.gov/study/NCT06007677","title":"A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients With Hereditary Angioedema (The ALPHA-SOLAR Trial)","has_exemption":false,"start_date":"2023-09-26","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Astria Therapeutics, Inc.","sponsor_slug":"astria-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06839456","publication_url":"https://clinicaltrials.gov/study/NCT06839456","title":"Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant","has_exemption":false,"start_date":"2025-03-21","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital of Philadelphia","sponsor_slug":"childrens-hospital-of-philadelphia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06907875","publication_url":"https://clinicaltrials.gov/study/NCT06907875","title":"A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients","has_exemption":false,"start_date":"2025-05-08","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Epicrispr Biotechnologies, Inc.","sponsor_slug":"epicrispr-biotechnologies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07157774","publication_url":"https://clinicaltrials.gov/study/NCT07157774","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event","has_exemption":false,"start_date":"2025-09-02","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07202598","publication_url":"https://clinicaltrials.gov/study/NCT07202598","title":"A Phase 2 Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis","has_exemption":false,"start_date":"2025-11-12","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","sponsor_slug":"national-institute-of-allergy-and-infectious-diseases-niaid","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07325487","publication_url":"https://clinicaltrials.gov/study/NCT07325487","title":"Adaptive Deep Brain Stimulation Targeting the Interposed Nucleus to Treat Spinocerebellar Ataxia","has_exemption":false,"start_date":"2026-03-31","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Florida","sponsor_slug":"university-of-florida","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07179003","publication_url":"https://clinicaltrials.gov/study/NCT07179003","title":"A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Rochester","sponsor_slug":"university-of-rochester","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07549321","publication_url":"https://clinicaltrials.gov/study/NCT07549321","title":"A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination With Chemotherapy in Participants With High-Risk Neuroblastoma","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Renaissance Pharma Ltd.","sponsor_slug":"renaissance-pharma-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04756063","publication_url":"https://clinicaltrials.gov/study/NCT04756063","title":"Parenteral Ascorbic Acid Repletion in TransplantatIon (PARTI): A Randomized, Double-Blinded, Placebo-Controlled Trial","has_exemption":false,"start_date":"2026-05-31","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Wisconsin, Madison","sponsor_slug":"university-of-wisconsin-madison","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07303816","publication_url":"https://clinicaltrials.gov/study/NCT07303816","title":"STAT-CAT: Statin Therapy to Prevent Cancer Associated Venous Thromboembolism","has_exemption":false,"start_date":"2026-06-11","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Brigham and Women's Hospital","sponsor_slug":"brigham-and-womens-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07466316","publication_url":"https://clinicaltrials.gov/study/NCT07466316","title":"A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) Versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma","has_exemption":false,"start_date":"2026-06-22","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07346209","publication_url":"https://clinicaltrials.gov/study/NCT07346209","title":"STudy of Real-world Individualized Precision-oncology","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Diego","sponsor_slug":"university-of-california-san-diego","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07346157","publication_url":"https://clinicaltrials.gov/study/NCT07346157","title":"PNOC044: Liothyronine (L-T3) in Combination With Bevacizumab, Irinotecan and Temozolomide (BIT) for Progressive or Relapsed Medulloblastoma (Cohort 1) or as Monotherapy for Medulloblastoma With Minimal Residual Disease (Cohort 2)","has_exemption":false,"start_date":"2026-07-30","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Sabine Mueller, MD, PhD","sponsor_slug":"sabine-mueller-md-phd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07503782","publication_url":"https://clinicaltrials.gov/study/NCT07503782","title":"Investigating Oleoylethanolamide (OEA) as a Novel Multi-System Based Therapeutic for Young Adults With Alcohol Use Disorder","has_exemption":false,"start_date":"2026-08-01","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Medical University of South Carolina","sponsor_slug":"medical-university-of-south-carolina","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04387305","publication_url":"https://clinicaltrials.gov/study/NCT04387305","title":"Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study","has_exemption":false,"start_date":"2026-10-01","completion_date":"2031-03-31","has_results":false,"results_due":false,"sponsor_name":"Daniel Nishijima, MD, MAS","sponsor_slug":"daniel-nishijima-md-mas","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06785415","publication_url":"https://clinicaltrials.gov/study/NCT06785415","title":"Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma","has_exemption":false,"start_date":"2025-03-18","completion_date":"2031-04-01","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06863272","publication_url":"https://clinicaltrials.gov/study/NCT06863272","title":"MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)","has_exemption":false,"start_date":"2025-07-03","completion_date":"2031-04-01","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07227454","publication_url":"https://clinicaltrials.gov/study/NCT07227454","title":"A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or Behavior","has_exemption":false,"start_date":"2026-01-08","completion_date":"2031-04-09","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05367440","publication_url":"https://clinicaltrials.gov/study/NCT05367440","title":"A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)","has_exemption":false,"start_date":"2022-06-02","completion_date":"2031-04-11","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06408259","publication_url":"https://clinicaltrials.gov/study/NCT06408259","title":"A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis","has_exemption":false,"start_date":"2025-04-08","completion_date":"2031-04-11","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07636564","publication_url":"https://clinicaltrials.gov/study/NCT07636564","title":"A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)","has_exemption":false,"start_date":"2026-10-14","completion_date":"2031-04-16","has_results":false,"results_due":false,"sponsor_name":"SWOG Cancer Research Network","sponsor_slug":"swog-cancer-research-network","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06912698","publication_url":"https://clinicaltrials.gov/study/NCT06912698","title":"A Phase III Randomized Controlled Non-Inferiority Clinical Trial Comparing Reduced-Dose Versus Standard-Dose Radiotherapy Based on Treatment Response in Early-Stage Nasopharyngeal Carcinoma","has_exemption":false,"start_date":"2025-05-22","completion_date":"2031-04-19","has_results":false,"results_due":false,"sponsor_name":"Hai-Qiang Mai,MD,PhD","sponsor_slug":"hai-qiang-maimdphd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05675410","publication_url":"https://clinicaltrials.gov/study/NCT05675410","title":"A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma","has_exemption":false,"start_date":"2023-05-11","completion_date":"2031-04-28","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06679101","publication_url":"https://clinicaltrials.gov/study/NCT06679101","title":"A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","has_exemption":false,"start_date":"2024-12-16","completion_date":"2031-04-28","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01958086","publication_url":"https://clinicaltrials.gov/study/NCT01958086","title":"Visuomotor Prosthetic for Paralysis","has_exemption":false,"start_date":"2013-10-01","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"Richard A. Andersen, PhD","sponsor_slug":"richard-a-andersen-phd","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT05552222","publication_url":"https://clinicaltrials.gov/study/NCT05552222","title":"A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy","has_exemption":false,"start_date":"2022-10-25","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06799195","publication_url":"https://clinicaltrials.gov/study/NCT06799195","title":"A Phase II Randomized Trial to Optimize GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation in Older Adults With Hematological Malignancies: the PROMISE Trial","has_exemption":false,"start_date":"2025-06-23","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"University of Nebraska","sponsor_slug":"university-of-nebraska","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07227285","publication_url":"https://clinicaltrials.gov/study/NCT07227285","title":"Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"EG 427","sponsor_slug":"eg-427","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07558759","publication_url":"https://clinicaltrials.gov/study/NCT07558759","title":"Temporal Interference in Psychiatry (TIP): Neuromodulation Using Temporal Interference","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"Emory University","sponsor_slug":"emory-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07021937","publication_url":"https://clinicaltrials.gov/study/NCT07021937","title":"Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial","has_exemption":false,"start_date":"2026-05-01","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"University of Colorado, Denver","sponsor_slug":"university-of-colorado-denver","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07387549","publication_url":"https://clinicaltrials.gov/study/NCT07387549","title":"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis","has_exemption":false,"start_date":"2026-05-14","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"Ipsen","sponsor_slug":"ipsen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07332182","publication_url":"https://clinicaltrials.gov/study/NCT07332182","title":"Multicenter Prospective Randomized Study of MaioRegenTM Prime vs. Debridement (Surgical Standard of Care (SSOC)) for the Treatment of Osteochondral Lesion of the Knee Joint - OSTEOCONFIRM Study","has_exemption":false,"start_date":"2026-05-31","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"Fin-Ceramica Faenza Spa","sponsor_slug":"fin-ceramica-faenza-spa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06964230","publication_url":"https://clinicaltrials.gov/study/NCT06964230","title":"A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease","has_exemption":false,"start_date":"2026-10-26","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"T3D Therapeutics, Inc.","sponsor_slug":"t3d-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07485010","publication_url":"https://clinicaltrials.gov/study/NCT07485010","title":"A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","has_exemption":false,"start_date":"2027-04-30","completion_date":"2031-04-30","has_results":false,"results_due":false,"sponsor_name":"The University of Queensland","sponsor_slug":"the-university-of-queensland","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05991388","publication_url":"https://clinicaltrials.gov/study/NCT05991388","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","has_exemption":false,"start_date":"2024-05-02","completion_date":"2031-05-01","has_results":false,"results_due":false,"sponsor_name":"University of Birmingham","sponsor_slug":"university-of-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07457385","publication_url":"https://clinicaltrials.gov/study/NCT07457385","title":"Congenital Syphilis Treatment Trial (CONSISTENT): Phase IV, Open-label, Randomized Controlled Trial of Amoxicillin vs. Benzathine in Neonates With Possible Congenital Syphilis","has_exemption":false,"start_date":"2026-11-01","completion_date":"2031-05-01","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07288359","publication_url":"https://clinicaltrials.gov/study/NCT07288359","title":"An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors","has_exemption":false,"start_date":"2025-12-29","completion_date":"2031-05-09","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07468903","publication_url":"https://clinicaltrials.gov/study/NCT07468903","title":"Phase II Trial of Focal Radiation Therapy in Patients With Prostate Cancer","has_exemption":false,"start_date":"2026-05-11","completion_date":"2031-05-11","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07497607","publication_url":"https://clinicaltrials.gov/study/NCT07497607","title":"Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma (REDUCE-30)","has_exemption":false,"start_date":"2026-05-13","completion_date":"2031-05-13","has_results":false,"results_due":false,"sponsor_name":"Sara Medek","sponsor_slug":"sara-medek","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05253131","publication_url":"https://clinicaltrials.gov/study/NCT05253131","title":"Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors","has_exemption":false,"start_date":"2026-05-15","completion_date":"2031-05-15","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06710626","publication_url":"https://clinicaltrials.gov/study/NCT06710626","title":"CONVOY: An Early Feasibility Study of Neural Control of Assistive Devices Via Brain-Computer Interface Technology","has_exemption":false,"start_date":"2024-11-25","completion_date":"2031-05-25","has_results":false,"results_due":false,"sponsor_name":"Neuralink Corp","sponsor_slug":"neuralink-corp","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07613099","publication_url":"https://clinicaltrials.gov/study/NCT07613099","title":"Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET/CT Imaging)","has_exemption":false,"start_date":"2026-06-22","completion_date":"2031-05-26","has_results":false,"results_due":false,"sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","sponsor_slug":"national-heart-lung-and-blood-institute-nhlbi","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07444489","publication_url":"https://clinicaltrials.gov/study/NCT07444489","title":"An Open-Label Long-Term Extension Study for Participants From the 299AR301 Felzartamab Study","has_exemption":false,"start_date":"2026-04-16","completion_date":"2031-05-28","has_results":false,"results_due":false,"sponsor_name":"Biogen","sponsor_slug":"biogen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05561387","publication_url":"https://clinicaltrials.gov/study/NCT05561387","title":"A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of \"Intermediate Fit\" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance","has_exemption":false,"start_date":"2023-10-12","completion_date":"2031-05-30","has_results":false,"results_due":false,"sponsor_name":"SWOG Cancer Research Network","sponsor_slug":"swog-cancer-research-network","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06919003","publication_url":"https://clinicaltrials.gov/study/NCT06919003","title":"Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (RTB-021)","has_exemption":false,"start_date":"2025-09-22","completion_date":"2031-05-30","has_results":false,"results_due":false,"sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","sponsor_slug":"national-institute-of-allergy-and-infectious-diseases-niaid","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07650188","publication_url":"https://clinicaltrials.gov/study/NCT07650188","title":"Stimulating the Aging Brain: Noninvasive Brain and Sensory Stimulation Strategies in Aging","has_exemption":false,"start_date":"2026-06-01","completion_date":"2031-05-30","has_results":false,"results_due":false,"sponsor_name":"Medical College of Wisconsin","sponsor_slug":"medical-college-of-wisconsin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07650643","publication_url":"https://clinicaltrials.gov/study/NCT07650643","title":"EEG Biomarkers for Pediatric ADHD Treatment Stratification","has_exemption":false,"start_date":"2026-09-15","completion_date":"2031-05-30","has_results":false,"results_due":false,"sponsor_name":"Boston Children’s Hospital","sponsor_slug":"boston-childrens-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03314181","publication_url":"https://clinicaltrials.gov/study/NCT03314181","title":"A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma","has_exemption":false,"start_date":"2018-04-02","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04923958","publication_url":"https://clinicaltrials.gov/study/NCT04923958","title":"Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) Study","has_exemption":false,"start_date":"2021-04-14","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05856370","publication_url":"https://clinicaltrials.gov/study/NCT05856370","title":"The Ailliance Post-Market Clinical Study: All enablIng technoLogies, bioLogics, IDS, And Core spiNe produCt collEction","has_exemption":false,"start_date":"2023-05-01","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"Medtronic Spinal and Biologics","sponsor_slug":"medtronic-spinal-and-biologics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07543120","publication_url":"https://clinicaltrials.gov/study/NCT07543120","title":"A Multicenter Open-label Extension Study to Evaluate Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients.","has_exemption":false,"start_date":"2026-05-07","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07479797","publication_url":"https://clinicaltrials.gov/study/NCT07479797","title":"A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","has_exemption":false,"start_date":"2026-05-22","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"Kite, A Gilead Company","sponsor_slug":"kite-a-gilead-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07278362","publication_url":"https://clinicaltrials.gov/study/NCT07278362","title":"Safety of Intramuscular Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance","has_exemption":false,"start_date":"2026-05-31","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07428148","publication_url":"https://clinicaltrials.gov/study/NCT07428148","title":"Phase I/II Trial of Induction Lattice-Based Radiotherapy and Chemoimmunotherapy Preceding Response-Adapted Definitive Chemoradiation for Non-Low Risk Oropharyngeal Squamous Cell Carcinoma","has_exemption":false,"start_date":"2026-05-31","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"NYU Langone Health","sponsor_slug":"nyu-langone-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07472322","publication_url":"https://clinicaltrials.gov/study/NCT07472322","title":"UW26001 Phase I/II Study on the Safety, Tolerability, and Preliminary Efficacy of ASTX727 (Decitabine/Cedazuridine) and Retifanlimab-dlwr in Patients With Advanced Merkel Cell Carcinoma Who Have Progressed on Anti-PD-(L)1 Inhibitor","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Wisconsin, Madison","sponsor_slug":"university-of-wisconsin-madison","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07607665","publication_url":"https://clinicaltrials.gov/study/NCT07607665","title":"Paired Stimulation of Hand Motor Cortex and Median Nerve to Induce Spinal Cord Plasticity in Hemiplegic Cerebral Palsy","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"Columbia University","sponsor_slug":"columbia-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07636785","publication_url":"https://clinicaltrials.gov/study/NCT07636785","title":"A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"VM Discovery, Inc.","sponsor_slug":"vm-discovery-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07623187","publication_url":"https://clinicaltrials.gov/study/NCT07623187","title":"A Two-part, Phase 2b/Phase 3 Double-blinded, Randomized Study of IPN60340 in Combination With Azacitidine and Venetoclax Versus Placebo in Combination With Azacitidine and Venetoclax in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy.","has_exemption":false,"start_date":"2026-11-01","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"Ipsen","sponsor_slug":"ipsen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07167953","publication_url":"https://clinicaltrials.gov/study/NCT07167953","title":"MRI Technology for Greater Efficiency and Improved Value","has_exemption":false,"start_date":"2028-08-31","completion_date":"2031-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Wisconsin, Madison","sponsor_slug":"university-of-wisconsin-madison","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02375204","publication_url":"https://clinicaltrials.gov/study/NCT02375204","title":"A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors","has_exemption":false,"start_date":"2015-08-06","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"Alliance for Clinical Trials in Oncology","sponsor_slug":"alliance-for-clinical-trials-in-oncology","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT06967610","publication_url":"https://clinicaltrials.gov/study/NCT06967610","title":"Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).","has_exemption":false,"start_date":"2025-07-15","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07547917","publication_url":"https://clinicaltrials.gov/study/NCT07547917","title":"Improving the Measurement of Neonatal High Blood Pressure Using the Boppli Device","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"Indiana University","sponsor_slug":"indiana-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07565155","publication_url":"https://clinicaltrials.gov/study/NCT07565155","title":"A Phase 2 Trial of Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency","has_exemption":false,"start_date":"2026-06-01","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"Peter Hosein, MD","sponsor_slug":"peter-hosein-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07594015","publication_url":"https://clinicaltrials.gov/study/NCT07594015","title":"Phase 2 Open-Label Trial Investigating the Efficacy and Safety of Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy","has_exemption":false,"start_date":"2026-06-01","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07321912","publication_url":"https://clinicaltrials.gov/study/NCT07321912","title":"A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","has_exemption":false,"start_date":"2026-06-05","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"Milton S. Hershey Medical Center","sponsor_slug":"milton-s-hershey-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07158567","publication_url":"https://clinicaltrials.gov/study/NCT07158567","title":"Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low Back PaiN Treatment: VIBRANT","has_exemption":false,"start_date":"2026-07-01","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07415772","publication_url":"https://clinicaltrials.gov/study/NCT07415772","title":"The Effect of Right dlPFC cTBS on Acute Measures of Anxiety, Functional Connectivity, and TMS-evoked BOLD Responses.","has_exemption":false,"start_date":"2026-07-01","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04007276","publication_url":"https://clinicaltrials.gov/study/NCT04007276","title":"The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%","has_exemption":false,"start_date":"2026-11-10","completion_date":"2031-06-01","has_results":false,"results_due":false,"sponsor_name":"Tulane University","sponsor_slug":"tulane-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07340541","publication_url":"https://clinicaltrials.gov/study/NCT07340541","title":"TBCRC Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE-BDT)","has_exemption":false,"start_date":"2026-02-16","completion_date":"2031-06-02","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07604233","publication_url":"https://clinicaltrials.gov/study/NCT07604233","title":"Phase Ib/II of the Combination of Fludarabine, Cytarabine, Idarubicin, G-CSF (FLAG-Ida) With Venetoclax and Asciminib in Patients With Advanced Phase Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia","has_exemption":false,"start_date":"2026-11-30","completion_date":"2031-06-03","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06351592","publication_url":"https://clinicaltrials.gov/study/NCT06351592","title":"First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations","has_exemption":false,"start_date":"2024-08-28","completion_date":"2031-06-05","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04657822","publication_url":"https://clinicaltrials.gov/study/NCT04657822","title":"An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study","has_exemption":false,"start_date":"2021-06-10","completion_date":"2031-06-10","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07222553","publication_url":"https://clinicaltrials.gov/study/NCT07222553","title":"Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Immunoglobulin G4-related Disease (IgG4-RD)","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-06-10","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05769777","publication_url":"https://clinicaltrials.gov/study/NCT05769777","title":"An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","has_exemption":false,"start_date":"2023-04-03","completion_date":"2031-06-11","has_results":false,"results_due":false,"sponsor_name":"Sanofi","sponsor_slug":"sanofi","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02065011","publication_url":"https://clinicaltrials.gov/study/NCT02065011","title":"An Open-label Study to Determine the Long-term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B","has_exemption":false,"start_date":"2013-09-12","completion_date":"2031-06-13","has_results":false,"results_due":false,"sponsor_name":"Sanofi","sponsor_slug":"sanofi","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT06482684","publication_url":"https://clinicaltrials.gov/study/NCT06482684","title":"Early Treatment Intensification in Patients With High Risk Mantle Cell Lymphoma Using CAR-T-cell Treatment After an Abbreviated Induction Therapy With Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) as Compared to Standard of Care Induction and Maintenance (Arm B)","has_exemption":false,"start_date":"2024-02-15","completion_date":"2031-06-15","has_results":false,"results_due":false,"sponsor_name":"Christian Schmidt, MD","sponsor_slug":"christian-schmidt-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07646678","publication_url":"https://clinicaltrials.gov/study/NCT07646678","title":"A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants With Selected Central Hypersomnia Conditions","has_exemption":false,"start_date":"2026-06-10","completion_date":"2031-06-15","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05805826","publication_url":"https://clinicaltrials.gov/study/NCT05805826","title":"A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED WITH NOVEL ADJUVANTS IN HEALTHY ADULTS","has_exemption":false,"start_date":"2023-03-23","completion_date":"2031-06-19","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06363994","publication_url":"https://clinicaltrials.gov/study/NCT06363994","title":"A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) Vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma","has_exemption":false,"start_date":"2024-05-29","completion_date":"2031-06-25","has_results":false,"results_due":false,"sponsor_name":"InnoCare Pharma Inc.","sponsor_slug":"innocare-pharma-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06858319","publication_url":"https://clinicaltrials.gov/study/NCT06858319","title":"A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.","has_exemption":false,"start_date":"2025-07-28","completion_date":"2031-06-25","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06134375","publication_url":"https://clinicaltrials.gov/study/NCT06134375","title":"Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients With Breast Cancer at High Risk of Recurrence","has_exemption":false,"start_date":"2024-11-26","completion_date":"2031-06-26","has_results":false,"results_due":false,"sponsor_name":"Dartmouth-Hitchcock Medical Center","sponsor_slug":"dartmouth-hitchcock-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03424018","publication_url":"https://clinicaltrials.gov/study/NCT03424018","title":"A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia","has_exemption":false,"start_date":"2017-12-12","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"BioMarin Pharmaceutical","sponsor_slug":"biomarin-pharmaceutical","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04923126","publication_url":"https://clinicaltrials.gov/study/NCT04923126","title":"SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma","has_exemption":false,"start_date":"2021-06-21","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"St. Jude Children's Research Hospital","sponsor_slug":"st-jude-childrens-research-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05606614","publication_url":"https://clinicaltrials.gov/study/NCT05606614","title":"An Open-label Phase 1/2/3 Study Consisting of a Phase 1/2 Safety and Dose-escalation and Phase 3 Dose-expansion Study to Evaluate Safety and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy in Females With Rett Syndrome","has_exemption":false,"start_date":"2023-03-06","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Taysha Gene Therapies, Inc.","sponsor_slug":"taysha-gene-therapies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06278870","publication_url":"https://clinicaltrials.gov/study/NCT06278870","title":"Disitamab Vedotin in Combination With Pyrotinib Versus THP in the First-line Treatment for HER2-positive Advanced Breast Cancer, a Multicentre, Randomized, Double-blind Controlled, Phase III Trial","has_exemption":false,"start_date":"2023-09-06","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","sponsor_slug":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07204938","publication_url":"https://clinicaltrials.gov/study/NCT07204938","title":"A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants With Hereditary Angioedema - ORBIT-EXPANSE","has_exemption":false,"start_date":"2025-10-01","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Astria Therapeutics, Inc.","sponsor_slug":"astria-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07462507","publication_url":"https://clinicaltrials.gov/study/NCT07462507","title":"Investigation of Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1","has_exemption":false,"start_date":"2026-04-16","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07138274","publication_url":"https://clinicaltrials.gov/study/NCT07138274","title":"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Metyrapone in Subjects Diagnosed With Mild Autonomous Cortisol Secretion (MACS)","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07490301","publication_url":"https://clinicaltrials.gov/study/NCT07490301","title":"Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07480564","publication_url":"https://clinicaltrials.gov/study/NCT07480564","title":"ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females Aged >2 to <4 Years With Rett Syndrome","has_exemption":false,"start_date":"2026-05-08","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Taysha Gene Therapies, Inc.","sponsor_slug":"taysha-gene-therapies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07526948","publication_url":"https://clinicaltrials.gov/study/NCT07526948","title":"Vaginal Estradiol Versus Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms, Dysbiosis and Markers of Latency Reversal in Menopausal Women Living With HIV","has_exemption":false,"start_date":"2026-06-01","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Albert Einstein College of Medicine","sponsor_slug":"albert-einstein-college-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07630649","publication_url":"https://clinicaltrials.gov/study/NCT07630649","title":"Evaluation of the Safety and Tolerability of Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy in the Second (Contralateral) Eye of Participants With Bilateral Neovascular Age-related Macular Degeneration.","has_exemption":false,"start_date":"2026-06-02","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Adverum Biotechnologies, Inc.","sponsor_slug":"adverum-biotechnologies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07582120","publication_url":"https://clinicaltrials.gov/study/NCT07582120","title":"A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07325149","publication_url":"https://clinicaltrials.gov/study/NCT07325149","title":"Exoskeletal-assisted Walking Combined With Transcutaneous Spinal Cord Stimulation: Effect on Imaging and Serum Biomarkers of Skeletal Muscle Mass and Bone Strength.","has_exemption":false,"start_date":"2026-07-01","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Bronx VA Medical Center","sponsor_slug":"bronx-va-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06052956","publication_url":"https://clinicaltrials.gov/study/NCT06052956","title":"A Phase 2 Study to Assess Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses","has_exemption":false,"start_date":"2026-07-15","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"University of Rochester","sponsor_slug":"university-of-rochester","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07329153","publication_url":"https://clinicaltrials.gov/study/NCT07329153","title":"Neuronavigated and Non-Neuronavigated Accelerated Intermittent Theta-Burst Stimulation for Treatment-Resistant Depression A Sham-Controlled Randomized Controlled Trial","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"University of Texas Southwestern Medical Center","sponsor_slug":"university-of-texas-southwestern-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07635056","publication_url":"https://clinicaltrials.gov/study/NCT07635056","title":"Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital Medical Center, Cincinnati","sponsor_slug":"childrens-hospital-medical-center-cincinnati","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07449299","publication_url":"https://clinicaltrials.gov/study/NCT07449299","title":"Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel","has_exemption":false,"start_date":"2027-03-31","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"University of Utah","sponsor_slug":"university-of-utah","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06699966","publication_url":"https://clinicaltrials.gov/study/NCT06699966","title":"Stony Brook Medicine Anti-Inflammatory Trial","has_exemption":false,"start_date":"2027-06-30","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Stony Brook University","sponsor_slug":"stony-brook-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06545695","publication_url":"https://clinicaltrials.gov/study/NCT06545695","title":"Epidermal Growth Factor Receptor Inhibition for Keratinopathies","has_exemption":false,"start_date":"2027-07-01","completion_date":"2031-06-30","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04990921","publication_url":"https://clinicaltrials.gov/study/NCT04990921","title":"A Phase 2 Study of Palliative Radiation in Combination with Pembrolizumab in Subjects with Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink","has_exemption":false,"start_date":"2021-09-02","completion_date":"2031-07-01","has_results":false,"results_due":false,"sponsor_name":"University of Louisville","sponsor_slug":"university-of-louisville","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07508995","publication_url":"https://clinicaltrials.gov/study/NCT07508995","title":"A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)","has_exemption":false,"start_date":"2026-09-01","completion_date":"2031-07-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05929664","publication_url":"https://clinicaltrials.gov/study/NCT05929664","title":"Neoadjuvant REGN2810 (Cemiplimab) or REGN2810 (Cemiplimab) Plus REGN3767 (Fianlimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck","has_exemption":false,"start_date":"2023-07-05","completion_date":"2031-07-05","has_results":false,"results_due":false,"sponsor_name":"Thomas Jefferson University","sponsor_slug":"thomas-jefferson-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07232602","publication_url":"https://clinicaltrials.gov/study/NCT07232602","title":"A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D","has_exemption":false,"start_date":"2026-02-09","completion_date":"2031-07-08","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07493304","publication_url":"https://clinicaltrials.gov/study/NCT07493304","title":"A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants With Solid and Hematologic Cancers (ROXI-CAT-II)","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-07-08","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07392892","publication_url":"https://clinicaltrials.gov/study/NCT07392892","title":"A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA","has_exemption":false,"start_date":"2026-05-14","completion_date":"2031-07-22","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06538337","publication_url":"https://clinicaltrials.gov/study/NCT06538337","title":"Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers (HERA Trial)","has_exemption":false,"start_date":"2024-07-24","completion_date":"2031-07-26","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07598825","publication_url":"https://clinicaltrials.gov/study/NCT07598825","title":"A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis","has_exemption":false,"start_date":"2026-09-07","completion_date":"2031-07-30","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03773965","publication_url":"https://clinicaltrials.gov/study/NCT03773965","title":"A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)","has_exemption":false,"start_date":"2019-04-05","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05905926","publication_url":"https://clinicaltrials.gov/study/NCT05905926","title":"An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 6 to Less Than 18 Years Old","has_exemption":false,"start_date":"2023-02-17","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Ardelyx","sponsor_slug":"ardelyx","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05864534","publication_url":"https://clinicaltrials.gov/study/NCT05864534","title":"A Phase 2a Trial of Immune Modulation in Combination With Ultrasound-mediated Blood Brain Barrier Opening in Patients With Newly Diagnosed Glioblastoma","has_exemption":false,"start_date":"2024-01-19","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05952934","publication_url":"https://clinicaltrials.gov/study/NCT05952934","title":"A Phase II Clinical Trial of Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence","has_exemption":false,"start_date":"2024-02-12","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"University of Arkansas","sponsor_slug":"university-of-arkansas","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06789913","publication_url":"https://clinicaltrials.gov/study/NCT06789913","title":"A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation","has_exemption":false,"start_date":"2025-06-13","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Relay Therapeutics, Inc.","sponsor_slug":"relay-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06899152","publication_url":"https://clinicaltrials.gov/study/NCT06899152","title":"HepQuant: Pilot Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer","has_exemption":false,"start_date":"2025-07-16","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Montefiore Medical Center","sponsor_slug":"montefiore-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06948786","publication_url":"https://clinicaltrials.gov/study/NCT06948786","title":"PROMOTE-FL: Pirtobrutinib and Mosunetuzumab to Enhance Treatment Efficacy for Patients With Relapsed/Refractory Follicular Lymphoma","has_exemption":false,"start_date":"2025-11-17","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"University of Washington","sponsor_slug":"university-of-washington","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07128381","publication_url":"https://clinicaltrials.gov/study/NCT07128381","title":"Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)","has_exemption":false,"start_date":"2026-01-02","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07222137","publication_url":"https://clinicaltrials.gov/study/NCT07222137","title":"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years","has_exemption":false,"start_date":"2026-01-12","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07226206","publication_url":"https://clinicaltrials.gov/study/NCT07226206","title":"A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07232069","publication_url":"https://clinicaltrials.gov/study/NCT07232069","title":"Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis","has_exemption":false,"start_date":"2026-07-01","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Duke University","sponsor_slug":"duke-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07506512","publication_url":"https://clinicaltrials.gov/study/NCT07506512","title":"Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07602166","publication_url":"https://clinicaltrials.gov/study/NCT07602166","title":"Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Vanderbilt University Medical Center","sponsor_slug":"vanderbilt-university-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07655440","publication_url":"https://clinicaltrials.gov/study/NCT07655440","title":"Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07174414","publication_url":"https://clinicaltrials.gov/study/NCT07174414","title":"Cilostazol for Prevention of Recurrent Stroke Trial","has_exemption":false,"start_date":"2026-08-31","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07408583","publication_url":"https://clinicaltrials.gov/study/NCT07408583","title":"A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses","has_exemption":false,"start_date":"2028-01-31","completion_date":"2031-07-31","has_results":false,"results_due":false,"sponsor_name":"Agnieszka Czechowicz","sponsor_slug":"agnieszka-czechowicz","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06990737","publication_url":"https://clinicaltrials.gov/study/NCT06990737","title":"Phase 2 Pragmatic Trial Investigating Sentinel Lymph Node Biopsy (SLNB) Efficacy and Safety in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck","has_exemption":false,"start_date":"2025-06-25","completion_date":"2031-08-01","has_results":false,"results_due":false,"sponsor_name":"University of California, Davis","sponsor_slug":"university-of-california-davis","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06866262","publication_url":"https://clinicaltrials.gov/study/NCT06866262","title":"Phase I/II Trial of Inulin Gel in Combination With Ipilimumab and Nivolumab in Advanced Renal Cell Carcinoma [ICON Trial]","has_exemption":false,"start_date":"2025-08-15","completion_date":"2031-08-01","has_results":false,"results_due":false,"sponsor_name":"University of Michigan Rogel Cancer Center","sponsor_slug":"university-of-michigan-rogel-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07570966","publication_url":"https://clinicaltrials.gov/study/NCT07570966","title":"An Open-label, Multi-center, Phase I/II Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-08-01","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07286149","publication_url":"https://clinicaltrials.gov/study/NCT07286149","title":"KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-08-11","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07063745","publication_url":"https://clinicaltrials.gov/study/NCT07063745","title":"A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","has_exemption":false,"start_date":"2026-01-02","completion_date":"2031-08-12","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06568172","publication_url":"https://clinicaltrials.gov/study/NCT06568172","title":"Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (C-PRE)","has_exemption":false,"start_date":"2025-02-18","completion_date":"2031-08-14","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06940297","publication_url":"https://clinicaltrials.gov/study/NCT06940297","title":"DART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy","has_exemption":false,"start_date":"2025-06-23","completion_date":"2031-08-15","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07630974","publication_url":"https://clinicaltrials.gov/study/NCT07630974","title":"LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors","has_exemption":false,"start_date":"2026-07-28","completion_date":"2031-08-17","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07346196","publication_url":"https://clinicaltrials.gov/study/NCT07346196","title":"A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck","has_exemption":false,"start_date":"2027-02-07","completion_date":"2031-08-22","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07509151","publication_url":"https://clinicaltrials.gov/study/NCT07509151","title":"A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)","has_exemption":false,"start_date":"2026-05-05","completion_date":"2031-08-29","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06922318","publication_url":"https://clinicaltrials.gov/study/NCT06922318","title":"A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)","has_exemption":false,"start_date":"2025-08-19","completion_date":"2031-08-30","has_results":false,"results_due":false,"sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsor_slug":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07228221","publication_url":"https://clinicaltrials.gov/study/NCT07228221","title":"iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)","has_exemption":false,"start_date":"2026-01-05","completion_date":"2031-08-30","has_results":false,"results_due":false,"sponsor_name":"Jonathon Myers","sponsor_slug":"jonathon-myers","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT00969111","publication_url":"https://clinicaltrials.gov/study/NCT00969111","title":"Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy","has_exemption":false,"start_date":"2009-08-31","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Proton Collaborative Group","sponsor_slug":"proton-collaborative-group","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT04895709","publication_url":"https://clinicaltrials.gov/study/NCT04895709","title":"A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","has_exemption":false,"start_date":"2021-05-27","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04933721","publication_url":"https://clinicaltrials.gov/study/NCT04933721","title":"An Open-label Study to Provide Berotralstat Access to Subjects With Type 1 and 2 Hereditary Angioedema Who Were Previously Enrolled in Berotralstat Studies","has_exemption":false,"start_date":"2021-07-23","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"BioCryst Pharmaceuticals","sponsor_slug":"biocryst-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06790784","publication_url":"https://clinicaltrials.gov/study/NCT06790784","title":"A Randomized Clinical Trial Evaluating Combination Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of Proliferative Diabetic Retinopathy","has_exemption":false,"start_date":"2025-08-04","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Jaeb Center for Health Research","sponsor_slug":"jaeb-center-for-health-research","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06441006","publication_url":"https://clinicaltrials.gov/study/NCT06441006","title":"Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)","has_exemption":false,"start_date":"2025-10-03","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07322146","publication_url":"https://clinicaltrials.gov/study/NCT07322146","title":"Comparing Two Durations of Antibiotic Treatment for Children Hospitalized With Common Infections","has_exemption":false,"start_date":"2026-02-13","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06639607","publication_url":"https://clinicaltrials.gov/study/NCT06639607","title":"Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07558265","publication_url":"https://clinicaltrials.gov/study/NCT07558265","title":"WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Ohio State University","sponsor_slug":"ohio-state-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02448173","publication_url":"https://clinicaltrials.gov/study/NCT02448173","title":"A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer","has_exemption":false,"start_date":"2026-08-31","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Vaccinogen Inc","sponsor_slug":"vaccinogen-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07634562","publication_url":"https://clinicaltrials.gov/study/NCT07634562","title":"A Phase 1-2 Prospective Study to Evaluate the Safety and Feasibility of Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) in Liver Transplantation Recipients to Induce Immune Tolerance","has_exemption":false,"start_date":"2026-08-31","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07605923","publication_url":"https://clinicaltrials.gov/study/NCT07605923","title":"Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction","has_exemption":false,"start_date":"2026-09-30","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05155033","publication_url":"https://clinicaltrials.gov/study/NCT05155033","title":"Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma","has_exemption":false,"start_date":"2022-08-18","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06188741","publication_url":"https://clinicaltrials.gov/study/NCT06188741","title":"Phase 2 Trial of Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity in Neurofibromatosis Type 1","has_exemption":false,"start_date":"2025-08-27","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07392580","publication_url":"https://clinicaltrials.gov/study/NCT07392580","title":"A Single-Arm, Open-Label Study of Intralesional Treatment of Laryngeal Squamous Cell Carcinoma With Cisplatin","has_exemption":false,"start_date":"2026-09-01","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07649291","publication_url":"https://clinicaltrials.gov/study/NCT07649291","title":"Duloxetine Plus Exercise to Improve Physical Function in Veterans With Knee Osteoarthritis, Pain, and Psychological Comorbidity","has_exemption":false,"start_date":"2027-03-01","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06833073","publication_url":"https://clinicaltrials.gov/study/NCT06833073","title":"A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)","has_exemption":false,"start_date":"2025-03-11","completion_date":"2031-09-03","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06247995","publication_url":"https://clinicaltrials.gov/study/NCT06247995","title":"A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","has_exemption":false,"start_date":"2024-08-14","completion_date":"2031-09-09","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04929028","publication_url":"https://clinicaltrials.gov/study/NCT04929028","title":"Risk-Adapted Therapy for HIV-Associated Anal Cancer","has_exemption":false,"start_date":"2022-08-09","completion_date":"2031-09-15","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07498335","publication_url":"https://clinicaltrials.gov/study/NCT07498335","title":"A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN)","has_exemption":false,"start_date":"2026-08-26","completion_date":"2031-09-15","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02919592","publication_url":"https://clinicaltrials.gov/study/NCT02919592","title":"MemoryShape® and MemoryGel® Breast Implants Post Approval New Enrollment Study (\"Glow Study\")","has_exemption":false,"start_date":"2016-09-01","completion_date":"2031-09-16","has_results":false,"results_due":false,"sponsor_name":"Mentor Worldwide, LLC","sponsor_slug":"mentor-worldwide-llc","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT05627362","publication_url":"https://clinicaltrials.gov/study/NCT05627362","title":"A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC).","has_exemption":false,"start_date":"2022-12-29","completion_date":"2031-09-23","has_results":false,"results_due":false,"sponsor_name":"Ipsen","sponsor_slug":"ipsen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04245839","publication_url":"https://clinicaltrials.gov/study/NCT04245839","title":"A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","has_exemption":false,"start_date":"2020-07-14","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Celgene","sponsor_slug":"celgene","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07153796","publication_url":"https://clinicaltrials.gov/study/NCT07153796","title":"A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia","has_exemption":false,"start_date":"2026-01-30","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07283679","publication_url":"https://clinicaltrials.gov/study/NCT07283679","title":"Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma","has_exemption":false,"start_date":"2026-02-24","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07164469","publication_url":"https://clinicaltrials.gov/study/NCT07164469","title":"Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma","has_exemption":false,"start_date":"2026-06-28","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07321899","publication_url":"https://clinicaltrials.gov/study/NCT07321899","title":"Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER","has_exemption":false,"start_date":"2026-06-30","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Medtronic Cardiovascular","sponsor_slug":"medtronic-cardiovascular","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07178912","publication_url":"https://clinicaltrials.gov/study/NCT07178912","title":"Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)","has_exemption":false,"start_date":"2026-08-27","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07468916","publication_url":"https://clinicaltrials.gov/study/NCT07468916","title":"Ropeginterferon Alfa-2b for MDS/MPN Overlap Syndromes, Including CMML and MDS/MPN-RS-T","has_exemption":false,"start_date":"2026-09-29","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07528326","publication_url":"https://clinicaltrials.gov/study/NCT07528326","title":"TRiCares Topaz Transcatheter Tricuspid Heart Valve Replacement System IDE Pivotal Study","has_exemption":false,"start_date":"2026-10-31","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"TRiCares","sponsor_slug":"tricares","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07214896","publication_url":"https://clinicaltrials.gov/study/NCT07214896","title":"HEALTH: Humanoid Evaluation and Learning Trial in Coalition-Aligned Healthcare Settings","has_exemption":false,"start_date":"2025-10-06","completion_date":"2031-10-06","has_results":false,"results_due":false,"sponsor_name":"Truway Health, Inc.","sponsor_slug":"truway-health-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07361510","publication_url":"https://clinicaltrials.gov/study/NCT07361510","title":"ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.","has_exemption":false,"start_date":"2026-03-12","completion_date":"2031-10-14","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05624996","publication_url":"https://clinicaltrials.gov/study/NCT05624996","title":"Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2023-07-12","completion_date":"2031-10-15","has_results":false,"results_due":false,"sponsor_name":"NRG Oncology","sponsor_slug":"nrg-oncology","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07136012","publication_url":"https://clinicaltrials.gov/study/NCT07136012","title":"A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)","has_exemption":false,"start_date":"2025-08-22","completion_date":"2031-10-20","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07013487","publication_url":"https://clinicaltrials.gov/study/NCT07013487","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age","has_exemption":false,"start_date":"2025-06-11","completion_date":"2031-10-24","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07049926","publication_url":"https://clinicaltrials.gov/study/NCT07049926","title":"A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy","has_exemption":false,"start_date":"2025-07-20","completion_date":"2031-10-26","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07216703","publication_url":"https://clinicaltrials.gov/study/NCT07216703","title":"A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)","has_exemption":false,"start_date":"2026-01-19","completion_date":"2031-10-29","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05951179","publication_url":"https://clinicaltrials.gov/study/NCT05951179","title":"A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer","has_exemption":false,"start_date":"2023-09-15","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Protara Therapeutics","sponsor_slug":"protara-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06236438","publication_url":"https://clinicaltrials.gov/study/NCT06236438","title":"A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2024-04-10","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06013423","publication_url":"https://clinicaltrials.gov/study/NCT06013423","title":"Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics","has_exemption":false,"start_date":"2024-07-23","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Fred Hutchinson Cancer Center","sponsor_slug":"fred-hutchinson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06898450","publication_url":"https://clinicaltrials.gov/study/NCT06898450","title":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair","has_exemption":false,"start_date":"2025-03-31","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Nimbus Wadjet, Inc.","sponsor_slug":"nimbus-wadjet-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06563895","publication_url":"https://clinicaltrials.gov/study/NCT06563895","title":"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)","has_exemption":false,"start_date":"2025-05-12","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Eidos Therapeutics, a BridgeBio company","sponsor_slug":"eidos-therapeutics-a-bridgebio-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07110844","publication_url":"https://clinicaltrials.gov/study/NCT07110844","title":"A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis","has_exemption":false,"start_date":"2025-11-07","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Suzanne Lentzsch, MD","sponsor_slug":"suzanne-lentzsch-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07368998","publication_url":"https://clinicaltrials.gov/study/NCT07368998","title":"A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination With Fulvestrant in Participants With PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","has_exemption":false,"start_date":"2026-02-18","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07628101","publication_url":"https://clinicaltrials.gov/study/NCT07628101","title":"A Prospective Multi-Center, Single Arm, Open Label, Pivotal Clinical Study Designed to Assess the Safety, Performance, and Efficacy of the CardiaZn Stent in the Treatment of Pediatric Aortic Coarctation and Pulmonary Artery Stenosis","has_exemption":false,"start_date":"2026-10-31","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"PediaStent LLC","sponsor_slug":"pediastent-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03729817","publication_url":"https://clinicaltrials.gov/study/NCT03729817","title":"VERiTAS-2 REFRESH ICAS (REstoring Flow by REvascularization With Submaximal Angioplasty in Hemodynamic IntraCranial Atherosclerotic Stenosis)","has_exemption":false,"start_date":"2027-10-31","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Case Western Reserve University","sponsor_slug":"case-western-reserve-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07069595","publication_url":"https://clinicaltrials.gov/study/NCT07069595","title":"PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC With Residual Disease","has_exemption":false,"start_date":"2026-02-26","completion_date":"2031-11-01","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06934967","publication_url":"https://clinicaltrials.gov/study/NCT06934967","title":"An Open-label, Single-arm, Multicenter, Phase 3 Study to Assess Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric PNH Patients 2 to <18 Years of Age","has_exemption":false,"start_date":"2025-10-28","completion_date":"2031-11-19","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07214467","publication_url":"https://clinicaltrials.gov/study/NCT07214467","title":"Individualized Adaptive Deep Brain Stimulation in Opioid Use Disorder","has_exemption":false,"start_date":"2025-10-24","completion_date":"2031-11-22","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06549595","publication_url":"https://clinicaltrials.gov/study/NCT06549595","title":"A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)","has_exemption":false,"start_date":"2024-08-07","completion_date":"2031-11-26","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05156398","publication_url":"https://clinicaltrials.gov/study/NCT05156398","title":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age","has_exemption":false,"start_date":"2022-02-28","completion_date":"2031-11-29","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06511453","publication_url":"https://clinicaltrials.gov/study/NCT06511453","title":"Remote Self-Administered Acupressure for Pain Management in Patients With Sickle Cell Disease","has_exemption":false,"start_date":"2024-03-07","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Indiana University","sponsor_slug":"indiana-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06969430","publication_url":"https://clinicaltrials.gov/study/NCT06969430","title":"A Phase 1/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","has_exemption":false,"start_date":"2025-05-30","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Debiopharm International SA","sponsor_slug":"debiopharm-international-sa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07007312","publication_url":"https://clinicaltrials.gov/study/NCT07007312","title":"Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia","has_exemption":false,"start_date":"2025-09-26","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Kura Oncology, Inc.","sponsor_slug":"kura-oncology-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07285239","publication_url":"https://clinicaltrials.gov/study/NCT07285239","title":"Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"PrECOG, LLC.","sponsor_slug":"precog-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06813014","publication_url":"https://clinicaltrials.gov/study/NCT06813014","title":"Sitagliptin&#39;s Effects on Glucose-stimulated Insulin Secretion and Oral Glucose","has_exemption":false,"start_date":"2026-12-31","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"University of Maryland, Baltimore","sponsor_slug":"university-of-maryland-baltimore","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05145010","publication_url":"https://clinicaltrials.gov/study/NCT05145010","title":"Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE","has_exemption":false,"start_date":"2021-12-06","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"QED Therapeutics, a BridgeBio company","sponsor_slug":"qed-therapeutics-a-bridgebio-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06851754","publication_url":"https://clinicaltrials.gov/study/NCT06851754","title":"Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency","has_exemption":false,"start_date":"2025-07-17","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","sponsor_slug":"eunice-kennedy-shriver-national-institute-of-child-health-and-human-development-nichd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05145309","publication_url":"https://clinicaltrials.gov/study/NCT05145309","title":"Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans","has_exemption":false,"start_date":"2026-11-15","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"University of Texas Southwestern Medical Center","sponsor_slug":"university-of-texas-southwestern-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07225972","publication_url":"https://clinicaltrials.gov/study/NCT07225972","title":"An Open-Label Prospective Randomized Trial of Family Donor-Derived ADV or CMV CTLs Plus Standard of Care (SOC) vs SOC Alone in Children, Adolescents and Young Adults Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Refractory ADV or CMV Infection/Viremia","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"New York Medical College","sponsor_slug":"new-york-medical-college","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07587593","publication_url":"https://clinicaltrials.gov/study/NCT07587593","title":"Comparative Effectiveness of Interventions to Prevent Infections and Other Complications Arising From Central Venous Access Devices: the IVCare Adaptive Platform Trial.","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"The University of Queensland","sponsor_slug":"the-university-of-queensland","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07389239","publication_url":"https://clinicaltrials.gov/study/NCT07389239","title":"A Phase I/IIA Study Evaluating the Safety and Efficacy of NY-ESO-1TCR/dnTGFBRII Engineered T Cells in Combination With Decitabine in Subjects With Recurrent or Treatment Refractory Ovarian Cancer and Other Advanced Malignancies","has_exemption":false,"start_date":"2026-06-23","completion_date":"2031-12-10","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06663332","publication_url":"https://clinicaltrials.gov/study/NCT06663332","title":"CNTO1959ISD3001: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis","has_exemption":false,"start_date":"2024-10-29","completion_date":"2031-12-12","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02128906","publication_url":"https://clinicaltrials.gov/study/NCT02128906","title":"A Randomized, Phase II Study of Definitive Radiotherapy With Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: an ERCC1 Biomarker Enrichment and Interaction Design","has_exemption":false,"start_date":"2013-12-23","completion_date":"2031-12-16","has_results":false,"results_due":false,"sponsor_name":"Christopher Wilke","sponsor_slug":"christopher-wilke","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT06632444","publication_url":"https://clinicaltrials.gov/study/NCT06632444","title":"A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis","has_exemption":false,"start_date":"2024-09-17","completion_date":"2031-12-27","has_results":false,"results_due":false,"sponsor_name":"Boehringer Ingelheim","sponsor_slug":"boehringer-ingelheim","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04580420","publication_url":"https://clinicaltrials.gov/study/NCT04580420","title":"A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis","has_exemption":false,"start_date":"2021-04-15","completion_date":"2031-12-30","has_results":false,"results_due":false,"sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","sponsor_slug":"dicerna-pharmaceuticals-inc-a-novo-nordisk-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06620302","publication_url":"https://clinicaltrials.gov/study/NCT06620302","title":"DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma","has_exemption":false,"start_date":"2025-06-12","completion_date":"2031-12-30","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01524211","publication_url":"https://clinicaltrials.gov/study/NCT01524211","title":"Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms","has_exemption":false,"start_date":"2012-01-25","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Baptist Health South Florida","sponsor_slug":"baptist-health-south-florida","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT01893307","publication_url":"https://clinicaltrials.gov/study/NCT01893307","title":"Phase III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck","has_exemption":false,"start_date":"2013-08-26","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02579967","publication_url":"https://clinicaltrials.gov/study/NCT02579967","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","has_exemption":false,"start_date":"2015-11-19","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03984643","publication_url":"https://clinicaltrials.gov/study/NCT03984643","title":"Algorithms for Programming DBS Systems for ET","has_exemption":false,"start_date":"2019-10-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of Minnesota","sponsor_slug":"university-of-minnesota","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04586166","publication_url":"https://clinicaltrials.gov/study/NCT04586166","title":"SASS: Randomized Trial of Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for Concomitant Management of Stress Urinary Incontinence During Minimally Invasive Sacrocolpopexy","has_exemption":false,"start_date":"2020-12-23","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04124341","publication_url":"https://clinicaltrials.gov/study/NCT04124341","title":"Prefrontal Cortical Stimulation (PCS) for Severe Treatment Resistant Depression","has_exemption":false,"start_date":"2021-09-29","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of Minnesota","sponsor_slug":"university-of-minnesota","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05478304","publication_url":"https://clinicaltrials.gov/study/NCT05478304","title":"Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial","has_exemption":false,"start_date":"2023-01-25","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"AtriCure, Inc.","sponsor_slug":"atricure-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05071937","publication_url":"https://clinicaltrials.gov/study/NCT05071937","title":"Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer","has_exemption":false,"start_date":"2023-04-21","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Alexander B Olawaiye, MD","sponsor_slug":"alexander-b-olawaiye-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06134232","publication_url":"https://clinicaltrials.gov/study/NCT06134232","title":"An Open -Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE ® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response","has_exemption":false,"start_date":"2023-10-02","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Dendreon","sponsor_slug":"dendreon","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06428721","publication_url":"https://clinicaltrials.gov/study/NCT06428721","title":"The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population","has_exemption":false,"start_date":"2024-03-20","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Wright State University","sponsor_slug":"wright-state-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06483100","publication_url":"https://clinicaltrials.gov/study/NCT06483100","title":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","has_exemption":false,"start_date":"2024-12-20","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06529809","publication_url":"https://clinicaltrials.gov/study/NCT06529809","title":"Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer","has_exemption":false,"start_date":"2025-02-11","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06390956","publication_url":"https://clinicaltrials.gov/study/NCT06390956","title":"A Phase II Study of Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma","has_exemption":false,"start_date":"2025-02-20","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of Utah","sponsor_slug":"university-of-utah","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06951217","publication_url":"https://clinicaltrials.gov/study/NCT06951217","title":"A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])","has_exemption":false,"start_date":"2025-04-17","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Avalyn Pharma Inc.","sponsor_slug":"avalyn-pharma-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07114874","publication_url":"https://clinicaltrials.gov/study/NCT07114874","title":"A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia","has_exemption":false,"start_date":"2025-07-11","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Neurocrine Biosciences","sponsor_slug":"neurocrine-biosciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07070115","publication_url":"https://clinicaltrials.gov/study/NCT07070115","title":"A Prospective Study Evaluating Clinical Hiatal Hernia Outcomes Using OviTex® Reinforced Tissue Matrix","has_exemption":false,"start_date":"2025-07-25","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Tela Bio Inc","sponsor_slug":"tela-bio-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07005102","publication_url":"https://clinicaltrials.gov/study/NCT07005102","title":"A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2025-08-03","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07276438","publication_url":"https://clinicaltrials.gov/study/NCT07276438","title":"MRI- or CT-Guidance and Online Adaptation With Stereotactic Radiotherapy for Prostate Cancer (MANTICORE)","has_exemption":false,"start_date":"2025-12-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07195591","publication_url":"https://clinicaltrials.gov/study/NCT07195591","title":"Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)","has_exemption":false,"start_date":"2025-12-10","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"GT Medical Technologies, Inc.","sponsor_slug":"gt-medical-technologies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07447557","publication_url":"https://clinicaltrials.gov/study/NCT07447557","title":"A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of a Single Dose of ELP-02 Delivered Via Lumbar Intrathecal Administration in Charcot-Marie-Tooth-4J (CMT4J)","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Elpida Therapeutics SPC","sponsor_slug":"elpida-therapeutics-spc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07554521","publication_url":"https://clinicaltrials.gov/study/NCT07554521","title":"An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab Plus Chemotherapy in a First-Line Setting for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in US Racial and Ethnic Minority Patients","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"BeOne Medicines","sponsor_slug":"beone-medicines","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06694454","publication_url":"https://clinicaltrials.gov/study/NCT06694454","title":"Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2026-06-22","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07513623","publication_url":"https://clinicaltrials.gov/study/NCT07513623","title":"Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II","has_exemption":false,"start_date":"2026-07-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07001254","publication_url":"https://clinicaltrials.gov/study/NCT07001254","title":"Phase II Open-label Clinical Trial Evaluating Efficacy of Romiplostim Added to Standard of Care for Children and Young Adults With Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","has_exemption":false,"start_date":"2026-08-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Anjali Sharathkumar","sponsor_slug":"anjali-sharathkumar","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07542756","publication_url":"https://clinicaltrials.gov/study/NCT07542756","title":"Sequential Multiple Assignment Randomized Trial Comparing Commonly Prescribed and Over the Counter Medications for the Treatment of Insomnia in Adults","has_exemption":false,"start_date":"2026-05-01","completion_date":"2032-01-01","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06745076","publication_url":"https://clinicaltrials.gov/study/NCT06745076","title":"A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma","has_exemption":false,"start_date":"2025-03-06","completion_date":"2032-01-03","has_results":false,"results_due":false,"sponsor_name":"University of Washington","sponsor_slug":"university-of-washington","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06780111","publication_url":"https://clinicaltrials.gov/study/NCT06780111","title":"A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E","has_exemption":false,"start_date":"2025-07-30","completion_date":"2032-01-04","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06971939","publication_url":"https://clinicaltrials.gov/study/NCT06971939","title":"A Phase 4, Multicenter, Open-label Study to Evaluate Long-term Safety and Efficacy of Revakinagene Taroretcel-Lwey (NT-501) Previously Implanted During a Phase 1, Phase 2, or Phase 3 Clinical Study and to Evaluate NT-501 Implanted in Participants Who Underwent the Sham Procedure in a Phase 3 Clinical Study of Macular Telangiectasia Type 2 (MacTel)","has_exemption":false,"start_date":"2025-11-21","completion_date":"2032-01-15","has_results":false,"results_due":false,"sponsor_name":"Neurotech Pharmaceuticals","sponsor_slug":"neurotech-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07022678","publication_url":"https://clinicaltrials.gov/study/NCT07022678","title":"A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia","has_exemption":false,"start_date":"2026-05-26","completion_date":"2032-01-15","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07218887","publication_url":"https://clinicaltrials.gov/study/NCT07218887","title":"A Phase 1/2, Open-Label, Multicenter, Dose Finding and Dose Expansion Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants With BAG3 Mutation Associated Dilated Cardiomyopathy","has_exemption":false,"start_date":"2025-10-24","completion_date":"2032-01-27","has_results":false,"results_due":false,"sponsor_name":"Alexion Pharmaceuticals, Inc.","sponsor_slug":"alexion-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05789082","publication_url":"https://clinicaltrials.gov/study/NCT05789082","title":"A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","has_exemption":false,"start_date":"2023-06-20","completion_date":"2032-01-29","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07621796","publication_url":"https://clinicaltrials.gov/study/NCT07621796","title":"Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant (ESTER-DOAC)","has_exemption":false,"start_date":"2027-01-01","completion_date":"2032-01-30","has_results":false,"results_due":false,"sponsor_name":"Hackensack Meridian Health","sponsor_slug":"hackensack-meridian-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07214688","publication_url":"https://clinicaltrials.gov/study/NCT07214688","title":"A Phase 2 Study of Fludarabine and Intermediate-dose Total Body Irradiation (800 cGy) Followed by Post-transplant Cyclophosphamide in Patients Aged 18-65 Undergoing Allogeneic Stem Cell Transplant for Hematologic Malignancies","has_exemption":false,"start_date":"2026-01-06","completion_date":"2032-01-31","has_results":false,"results_due":false,"sponsor_name":"Hackensack Meridian Health","sponsor_slug":"hackensack-meridian-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07303894","publication_url":"https://clinicaltrials.gov/study/NCT07303894","title":"Randomized, Multi-dose, Placebo-controlled Phase 2 Trial of Oral Isoquercetin to Reduce Thrombin Generation in Ovarian Cancer","has_exemption":false,"start_date":"2026-01-22","completion_date":"2032-01-31","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07541170","publication_url":"https://clinicaltrials.gov/study/NCT07541170","title":"A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer","has_exemption":false,"start_date":"2026-09-01","completion_date":"2032-01-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06770582","publication_url":"https://clinicaltrials.gov/study/NCT06770582","title":"Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)","has_exemption":false,"start_date":"2025-06-03","completion_date":"2032-02-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06686121","publication_url":"https://clinicaltrials.gov/study/NCT06686121","title":"IMProving Mobility After revasCularizaTion in Peripheral Artery Disease: The IMPACT PAD Trial","has_exemption":false,"start_date":"2025-08-04","completion_date":"2032-02-01","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06788912","publication_url":"https://clinicaltrials.gov/study/NCT06788912","title":"KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-03-20","completion_date":"2032-02-06","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04165070","publication_url":"https://clinicaltrials.gov/study/NCT04165070","title":"KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2019-12-19","completion_date":"2032-02-13","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05533697","publication_url":"https://clinicaltrials.gov/study/NCT05533697","title":"Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","has_exemption":false,"start_date":"2022-09-01","completion_date":"2032-02-18","has_results":false,"results_due":false,"sponsor_name":"ModernaTX, Inc.","sponsor_slug":"modernatx-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06057402","publication_url":"https://clinicaltrials.gov/study/NCT06057402","title":"ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES","has_exemption":false,"start_date":"2023-10-03","completion_date":"2032-02-22","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06807281","publication_url":"https://clinicaltrials.gov/study/NCT06807281","title":"A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis","has_exemption":false,"start_date":"2025-12-02","completion_date":"2032-02-22","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07195695","publication_url":"https://clinicaltrials.gov/study/NCT07195695","title":"Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations","has_exemption":false,"start_date":"2026-01-16","completion_date":"2032-02-26","has_results":false,"results_due":false,"sponsor_name":"Boehringer Ingelheim","sponsor_slug":"boehringer-ingelheim","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07227402","publication_url":"https://clinicaltrials.gov/study/NCT07227402","title":"A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)","has_exemption":false,"start_date":"2025-11-26","completion_date":"2032-02-27","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04774718","publication_url":"https://clinicaltrials.gov/study/NCT04774718","title":"A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available","has_exemption":false,"start_date":"2021-09-14","completion_date":"2032-02-28","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05788536","publication_url":"https://clinicaltrials.gov/study/NCT05788536","title":"A Phase 1/2, Open-Label, Multicenter Trial With a Single Ascending Dose Cohort With Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tolerability, and Efficacy of DB-OTO in Children and Infants With Biallelic hOTOF Mutations","has_exemption":false,"start_date":"2023-06-27","completion_date":"2032-02-28","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06692712","publication_url":"https://clinicaltrials.gov/study/NCT06692712","title":"Intrathecal Administration of MELPIDA (AAV9/AP4M1) For Hereditary Spastic Paraplegia Type 50 (SPG50): A Phase 3, Open-Label Trial With Matched Prospective Concurrent Control Arm","has_exemption":false,"start_date":"2026-04-01","completion_date":"2032-02-28","has_results":false,"results_due":false,"sponsor_name":"Elpida Therapeutics SPC","sponsor_slug":"elpida-therapeutics-spc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05143840","publication_url":"https://clinicaltrials.gov/study/NCT05143840","title":"Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve Optimal Response or a Deep Molecular Remission (ALERT CML)","has_exemption":false,"start_date":"2022-04-22","completion_date":"2032-02-29","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06073821","publication_url":"https://clinicaltrials.gov/study/NCT06073821","title":"A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia","has_exemption":false,"start_date":"2023-11-11","completion_date":"2032-02-29","has_results":false,"results_due":false,"sponsor_name":"BeOne Medicines","sponsor_slug":"beone-medicines","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06544798","publication_url":"https://clinicaltrials.gov/study/NCT06544798","title":"Long-term Follow-up of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia","has_exemption":false,"start_date":"2024-08-02","completion_date":"2032-02-29","has_results":false,"results_due":false,"sponsor_name":"MeiraGTx, LLC","sponsor_slug":"meiragtx-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06788522","publication_url":"https://clinicaltrials.gov/study/NCT06788522","title":"The Effects of Orexin Antagonism on Fear Extinction in PTSD","has_exemption":false,"start_date":"2026-06-01","completion_date":"2032-03-01","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06780098","publication_url":"https://clinicaltrials.gov/study/NCT06780098","title":"KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-05-28","completion_date":"2032-03-02","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06731907","publication_url":"https://clinicaltrials.gov/study/NCT06731907","title":"KEYMAKER-U01 Substudy 01G: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-03-30","completion_date":"2032-03-12","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06780085","publication_url":"https://clinicaltrials.gov/study/NCT06780085","title":"KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-05-13","completion_date":"2032-03-12","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07022483","publication_url":"https://clinicaltrials.gov/study/NCT07022483","title":"A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)","has_exemption":false,"start_date":"2025-09-30","completion_date":"2032-03-23","has_results":false,"results_due":false,"sponsor_name":"Daiichi Sankyo","sponsor_slug":"daiichi-sankyo","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05682378","publication_url":"https://clinicaltrials.gov/study/NCT05682378","title":"An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20 or ORION-19 Studies (VICTORION-PEDS-OLE)","has_exemption":false,"start_date":"2023-02-10","completion_date":"2032-03-25","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06991556","publication_url":"https://clinicaltrials.gov/study/NCT06991556","title":"A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","has_exemption":false,"start_date":"2025-07-07","completion_date":"2032-03-29","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03959085","publication_url":"https://clinicaltrials.gov/study/NCT03959085","title":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy","has_exemption":false,"start_date":"2019-10-31","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06337318","publication_url":"https://clinicaltrials.gov/study/NCT06337318","title":"Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma","has_exemption":false,"start_date":"2024-10-23","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07110246","publication_url":"https://clinicaltrials.gov/study/NCT07110246","title":"A Phase 2 De-escalation Study of Dabrafenib and Trametinib for Patients With BRAF V600 Mutant Low-Grade Gliomas","has_exemption":false,"start_date":"2025-11-07","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07169279","publication_url":"https://clinicaltrials.gov/study/NCT07169279","title":"Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia","has_exemption":false,"start_date":"2025-11-19","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"QED Therapeutics, a BridgeBio company","sponsor_slug":"qed-therapeutics-a-bridgebio-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07294677","publication_url":"https://clinicaltrials.gov/study/NCT07294677","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","has_exemption":false,"start_date":"2026-03-17","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07645300","publication_url":"https://clinicaltrials.gov/study/NCT07645300","title":"LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD (LODESTAR) Trial","has_exemption":false,"start_date":"2026-10-01","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06649747","publication_url":"https://clinicaltrials.gov/study/NCT06649747","title":"A Double-blind, Placebo-controlled, Multi-center Phase II Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Oral AFA-281 in Patients With Painful Lumbosacral Radiculopathy","has_exemption":false,"start_date":"2027-04-01","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"Afasci Inc","sponsor_slug":"afasci-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07572747","publication_url":"https://clinicaltrials.gov/study/NCT07572747","title":"Aspirin Versus Clopidogrel for Secondary Prevention of Atherosclerotic Cardiovascular Events in Patients With Chronic Coronary Syndrome in the Arabian Gulf Countries: A Randomized, Open-label, Multi-Center Trial by the Gulf Trialists' Collaboration","has_exemption":false,"start_date":"2027-04-01","completion_date":"2032-04-01","has_results":false,"results_due":false,"sponsor_name":"Khalid F Alhabib","sponsor_slug":"khalid-f-alhabib","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07209111","publication_url":"https://clinicaltrials.gov/study/NCT07209111","title":"A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)","has_exemption":false,"start_date":"2025-12-04","completion_date":"2032-04-09","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05714085","publication_url":"https://clinicaltrials.gov/study/NCT05714085","title":"A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)","has_exemption":false,"start_date":"2023-05-31","completion_date":"2032-04-15","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06666322","publication_url":"https://clinicaltrials.gov/study/NCT06666322","title":"Platform Trial For Cryptococcal Meningitis","has_exemption":false,"start_date":"2025-05-28","completion_date":"2032-04-21","has_results":false,"results_due":false,"sponsor_name":"University of Minnesota","sponsor_slug":"university-of-minnesota","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04077099","publication_url":"https://clinicaltrials.gov/study/NCT04077099","title":"A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2020-01-07","completion_date":"2032-04-22","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07612254","publication_url":"https://clinicaltrials.gov/study/NCT07612254","title":"REPEAT: RE-irradiation With a Partial brEast, Accelerated Technique: A Single-Center, Multi-site, Prospective, Phase I/II Clinical Trial","has_exemption":false,"start_date":"2026-06-03","completion_date":"2032-04-28","has_results":false,"results_due":false,"sponsor_name":"Dartmouth-Hitchcock Medical Center","sponsor_slug":"dartmouth-hitchcock-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04093349","publication_url":"https://clinicaltrials.gov/study/NCT04093349","title":"Phase 1/2, Dose-escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults With Late-onset Pompe Disease","has_exemption":false,"start_date":"2020-10-01","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Spark Therapeutics, Inc.","sponsor_slug":"spark-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05031897","publication_url":"https://clinicaltrials.gov/study/NCT05031897","title":"A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning","has_exemption":false,"start_date":"2021-10-25","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Thomas Jefferson University","sponsor_slug":"thomas-jefferson-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05707949","publication_url":"https://clinicaltrials.gov/study/NCT05707949","title":"A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Migraine","has_exemption":false,"start_date":"2023-06-05","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05833763","publication_url":"https://clinicaltrials.gov/study/NCT05833763","title":"An Open-label, Single-arm, Phase 2 Trial of GlOfitamab anD pIrtobrutinib (LOXo-305) in Patients With Mantle Cell Lymphoma and Prior Exposure to a BTK Inhibitor","has_exemption":false,"start_date":"2023-10-12","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Australasian Leukaemia and Lymphoma Group","sponsor_slug":"australasian-leukaemia-and-lymphoma-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07550517","publication_url":"https://clinicaltrials.gov/study/NCT07550517","title":"A Phase II Non-blinded Randomized Study Comparing External Beam Radiotherapy (EBRT), 177Lu-PSMA-617, and Short Term Androgen Deprivation Therapy (ADT) Versus EBRT and Long Term ADT in Men With High Risk Localized Prostate Cancer","has_exemption":false,"start_date":"2026-04-30","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsor_slug":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07448610","publication_url":"https://clinicaltrials.gov/study/NCT07448610","title":"Onasemnogene Abeparvovec: ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)","has_exemption":false,"start_date":"2026-07-01","completion_date":"2032-05-03","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null}]}